Form 10-K NxStage Medical, Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Selloff in NxStage Medical (NXTM) Seems 'Excessive'; BTIG Reaffirms at 'Buy'
February 11, 2016 9:48 AM ESTBTIG is out in defense of NxStage Medical, Inc. (NXTM) following the company's Q4, FY16 results reported on Wednesday. The firm rates NxStage at Buy with a price target of $27.
Analyst Sean Lavin noted that NxStage posted FY16 revenue of $336 million, which exceeded the company's outlook of $332 - $333 million. But, a... More
